Leap Therapeutics, Inc. announced that its anti-Dickkopf-1 antibody, DKN-01, in combination with Merck’s anti-PD-1 antibody, Keytruda®, demonstrated higher survival and objective response outcomes in patients with advanced gastroesophageal junction and gastric cancer whose tumors expressed high levels of DKK1.
August 6, 2019
· 7 min read